PALM BEACH, Florida, October 26, 2017 /PRNewswire/ -- Medical devices are expected to display notable growth in the coming years as a result of rising incidence of infectious diseases along with the rising popularity of non-invasive diagnostic practices. Various products available in the medical devices market are segmented into therapeutic devices, diagnostic and monitoring devices, and injury prevention and rehabilitation devices which are all expected to an exhibit excellent growth rate in the coming years as innovation and advancements in healthcare technologies pick up with a significant pace. According to Transparency Market Research, the future worth of the global diagnostic medical devices and mHealth monitoring market is to be around US$8 Billion in 2019. Its valuation in 2012 was around US$600 Million. If these figures hold true, the global diagnostic medical devices and mHealth monitoring market will exhibit a whopping CAGR of 43.30% between 2013 and 2019. Active healthcare stocks in news today include: BioSig Technologies, Inc. (OTC: BSGM), Intuitive Surgical Inc. (NASDAQ: ISRG), Mazor Robotics Ltd. (NASDAQ: MZOR), NuVasive Inc. (NASDAQ: NUVA), Baxter International Inc. (NYSE: BAX).

BioSig Technologies, Inc . (OTCQB: BSGM), a medical device company developing a proprietary platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that the Company has concluded a key part of the strategic planning project launched earlier this year in collaboration with Health Research International (HRI). Project goals included understanding and presenting the clinical relevance of BioSig's technology, pricing strategies, and envisioning optimal applications of BioSig's platform technology beyond EP.

As part of the study, HRI conducted a detailed survey of U.S. electrophysiologists primarily based in New York, Texas, Massachusetts, Florida, Pennsylvania and North Carolina. Among the factors interfering with effective ablations, the inability to record high quality unipolar signals and difficulty detecting small intracardiac signals were consistently reported. Read this and more news for BioSig Technologies at: http://www.marketnewsupdates.com/news/bsgm.html
Survey respondents rated all six features of PURE EP System as being 'Very Helpful' for their ablations, emphasizing overall noise reduction and improved signal clarity/accuracy as key benefits. Most respondents see signal clarity as paramount to the success of ablations and indicated interest in a technology that reduces 'noise'. PURE EP System's ability to shorten procedure time - including the ability to perform more complex ablations - was listed as its definitive economic benefit. These expected time savings were largely responsible for the attractive pricing recommended for PURE EP System.

Medical Devices Homepage